Medicine and Dentistry
COVID-19
100%
Arm
83%
Baricitinib
83%
Ravulizumab
83%
Placebo
83%
Seasonal Influenza
83%
Immunogenicity
83%
Influenza Vaccine
83%
COVID-19 Vaccine
83%
Adverse Event
59%
Reactogenicity
33%
Interim Analysis
18%
Complement Component C5
18%
Vaccine Efficacy
16%
Hazard Ratio
9%
Biomedical Research
9%
Intensive Care Unit
9%
Care Group
9%
Cardiovascular System
9%
Medical Research
9%
Extracorporeal Membrane Oxygenation
9%
Public Health
9%
Complement Activation
9%
Renal Failure
9%
Immunosuppressant
9%
Artificial Respiration
9%
Disease Severity
9%
Diseases
9%
Janus Kinase
9%
Janus Kinase 1
9%
Complement Component C5a
9%
Cytokine
9%
Hemagglutination Inhibition
8%
Injection Site
8%
Antibody Response
8%
Immune Response
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Table Salt
8%
Contraindication
8%
Anaphylaxis
8%
Myalgia
8%
Intramuscular Injection
8%
Pharmacology, Toxicology and Pharmaceutical Science
Ravulizumab
83%
Seasonal Influenza
83%
COVID-19 Vaccine
83%
Influenza Vaccine
83%
Placebo
83%
Live Attenuated Influenza Vaccine
83%
Immunogenicity
83%
Baricitinib
83%
Adverse Event
59%
Complement Component C5
18%
Vaccine Efficacy
16%
Disease Severity
9%
Janus Kinase 1
9%
Immunosuppressive Agent
9%
Pandemic
9%
Cytokine
9%
Kidney Failure
9%
Janus Kinase
9%
Repurposing
9%
Complement Component C5a
9%
Diseases
9%
Anaphylaxis
8%
SARS Coronavirus
8%
Intramuscular Injection
8%
Myalgia
8%
Table Salt
8%
Immunology and Microbiology
COVID-19
83%
Influenza Vaccine
83%
Influenza
83%
Immunogenicity
83%
Vaccine Efficacy
16%
Spike
8%
Anaphylaxis
8%
Immune Response
8%
Cell-Based Vaccine
8%
Antibody Response
8%
Muscle
8%
Severe Acute Respiratory Syndrome Coronavirus 2
8%
Hemagglutination Inhibition
8%
